# Deciphering the mechanism of action of 089, a compound impairing the fungal cell cycle

## Abstract

Fungal infections represent an increasingly relevant clinical problem, primarily because of the increased survival of severely immune-compromised patients. Despite the availability of active and selective drugs and of well-established prophylaxis, classical antifungals are often ineffective as resistance is frequently observed. The quest for anti-fungal drugs with novel mechanisms of action is thus important. Here we show that a new compound, 089, acts by arresting fungal cells in the G2 phase of the cell cycle through targeting of SWE1, a mechanism of action unexploited by current anti-fungal drugs. The cell cycle impairment also induces a modification of fungal cell morphology which makes fungal cells recognizable by immune cells. This new class of molecules holds promise to be a valuable source of novel antifungals, allowing the clearance of pathogenic fungi by both direct killing of the fungus and enhancing the recognition of the pathogen by the host immune system.

## Introduction

Over the past 20 years, the incidence of invasive fungal infections has increased1. While skin and nail infections have been estimated to affect ~25% of the total population worldwide, invasive fungal infections are uncommon, mainly affecting immuno-compromised patients who become more susceptible to fungal infections than healthy individuals2. Although invasive infections have an incidence much lower than superficial infections, the rate of mortality associated with invasive fungal infections is of particular concern, since it often exceeds 50% of the infected population2 and it is now estimated to be greater than mortality caused by malaria3,4. After the discovery of amphotericin B deoxycholate in the 1950s5, the discovery of new anti-fungal drugs has lagged behind the increasing need for their use. Amphotericin B is very effective for the treatment of a wide spectrum of fungal infections, but it has shown several side effects6. This led to the advent of new amphotericin B formulations and of a few new classes of anti-fungal, such as azoles and echinocandins7. Fungal infections are nowadays mainly treated with azole antifungals followed by candins. Yet the use of these new compounds and formulations is not sufficient to effectively treat fungal infections, mainly because of the insurgence of resistance in pathogenic fungi8. Thus, the quest for new anti-fungal drugs is urgent. For many years the budding yeast Saccharomyces cerevisiae has been chosen as one of the best cellular models for high-throughput identification of bioactive compounds and for their characterization. By using this approach, it is possible to identify new drugs with novel mechanisms of action. A new interest has grown in anti-fungal drugs able not only to kill the pathogenic fungus, but also to facilitate the host immune response9,10. Priming of the host immune response as an adjunct to conventional anti-fungal therapy represents a promising avenue to enhance the activity of antifungals. By exerting a direct pharmaco-therapeutic effect, fungal load may be directly reduced by the anti-fungal agent, thus providing time for the host to mount an effective immunologic program that will eradicate the invading pathogen without excessive inflammation. Several combined therapies where chemokines and cytokines are used in conjunction with classical antifungals have been proposed11. Voriconazole, fluconazole and echinocandins have been shown to stimulate the immune response through induction of regulatory chemokine and cytokine expression12,13,14. Here we show the mechanism of action of a new compound, 089 [(7R)-3-benzhydryl-2-oxo-5-phenyl-6,8-dioxa-3-aza-bicycle[3.2.1]octane-7-carboxyl-ethylamide, Fig. 1a]. This compound was identified in a chemical library encompassing small bi-cyclic molecules generated by combining tartaric acid and amino acids (BTAa)15. Our previous work showed that, the 089 compound had the highest anti-fungal activity against Saccharomyces cerevisiae strains (MIC, Minimal Inhibitory Concentration = 0.3 mM15) of the molecules in the library and was thus selected for further investigations. Here we show that this compound, by targeting the SWE1 gene, conserved among pathogenic and non-pathogenic fungi, induces an impairment of the cell cycle with a consequent modification of cell morphology. This effect finally results in an increased recognition of treated fungi by immune cells, thus making the 089 chemical class a promising group of antifungals with potential for immune modulation.

## Results

### Identification of the mechanism of action of the new anti-fungal drug in the model fungus, Saccharomyces cerevisiae

To identify the molecular mechanisms underlying the effects induced by the anti-fungal drug 089 (Fig. 1a)15, we carried out a combination of analyses in the model yeast S. cerevisiae providing complementary information. Homozygous and heterozygous barcoded deletion collection sequencing was combined with transcriptional analysis and in vivo validation tests (Fig. S1). The heterozygous and homozygous barcoded deletion collections were generated in the model yeast S. cerevisiae and have been widely used to identify the mechanism of action of new and well-characterized compounds16. Each strain composing the deletion collection is deleted in a single gene, and the deletion is recognizable by the presence of specific DNA sequences (the “barcodes”)17. Hence, all the deletion strains can be pooled and treated at once with the compound of interest. By treating the heterozygous barcoded deletion collection (HIP, HapoInsufficiency Profiling) with 089, we aimed to identify genes encoding proteins targeted by the treatment. In a heterozygous background, strains bearing a single copy of the target gene are more sensitive to the compound. Thus, a sub-lethal concentration of the anti-fungal is effective only against strains deleted in genes encoding proteins targeted by the anti-fungal. Because the deletion of a given gene could per se modify the growth ability of the strain, the results need to be compared to a control treatment (DMSO, the solvent used to dissolve the molecule of interest). Hence, we treated the deletion collections with a sub-lethal dose of 089 (0.2 mM, previously identified)15 or with a control treatment (DMSO), both treated for 20 generations at 27 °C in shaking culture and compared the relative abundances of each deletion strain. Fitness Defect (FD) scores were calculated for each deletion strain as the difference of the abundance of the strain in the control compared to that in the treatment (see materials and methods for further details). Aiming at the identification of targets, we searched for strains having positive FD in the heterozygous deletion collection (present at higher numbers in the control than in the treatment samples). 74 heterozygous deletion strains showed FD scores significantly different after the 089 treatment compared to the control (Fig. 1b). Among the strains having significantly different FD scores, only 14 strains showed positive FD scores, thus being candidates as 089 targets (Fig. 1b). To validate the results of the HIP analysis, we separately evaluated the effect of several 089 concentrations on the growth of the heterozygous deletion strains showing the highest significant FD and the highest clearance (the latter calculated as the difference in FD score between a given deletion strain and the deletion strains having the closest FD score) (Fig. 1c and Table S1). The YJL187C (SWE1) deletion strain was the most sensitive to the treatment, showing a high growth inhibition at the lowest tested concentration (0.1 mM, Mann-Whitney p < 0.05, Fig. 1c), three folds lower than the MIC evaluated for the wild-type strain. The morphogenesis checkpoint kinase Swe1p is one of the key regulators of the yeast cell cycle which regulates the G2/M transition and several other functions. This protein kinase acts by negatively regulating Cdc28p through phosphorylation, thus delaying mitosis and, when over-expressed, leads to cell cycle arrest in the G2 phase18. We also observed that the strain deleted in YBR133C (HSL7) showed a significant positive FD score in the HIP assay (Fig. 1b), but its killing by 089 was not confirmed in the single-strain assay (Fig. 1c). Hsl7p blocks the mitotic exit by means of Swe1p inhibition (by phosphorylation) and prevents Swe1p accumulation and ability to inhibit the cyclin complex composed of Cdc28p, Clb1p and Clb2p19.

### Homozygous deletion profiling analysis

The treatment of the homozygous barcoded deletion collection (HOP, HOmozygous deletion Profiling) with a sub-lethal concentration of the investigated compound (0.2 mM) allows the identification of pathways targeted by the treatment or involved in the response to it. Aiming at the assessment of the cell response to the treatment, we treated the homozygous deletion collection as the heterozygous deletion collection (see previous paragraph) and searched for strains having significantly different FD scores between the treatment with 089 and the control (DMSO). As expected, the number of deletion strains having significant FDs identified after the treatment with 089 was higher in the HOP compared to the HIP assay (92 strains the first, 74 the latter, Table S1 and Fig. 1b). The list of FDs significantly differing in the treatment with 089 compared to the control (Table S2) was analyzed by means of pathway signature analysis, which allows determination of gene sets (either pathways or sets of genes regulated by the same transcription factor) that are differentially represented in the compared conditions20. Positive HOP FD scores correspond to strains deleted in genes involved in the response to the treatment and negative HOP FD scores indicate strains deleted in genes (or involved in pathways) targeted by the treatment. Hence, the same interpretation can be used for pathway analysis. All the differentially represented gene sets were over-represented (Table S2). Several differentially represented gene sets were related to the cell cycle (Fig. 2a), thus supporting the targeting of Swe1p by the molecule: the cell cycle as described in the KEGG database21 and the genes regulated by Hog1p and Rme1p transcription factors22. In addition, gene sets related to the cell morphology (associated to YBR627W, Gat3p, Dot6p, Hms1p transcription factors’ activity, Fig. 2a) were over represented in HOP analysis.

### Pathway analysis on S. cerevisiae gene expression

To further contextualize the HIP and HOP results, the effect of the compound on the model yeast S. cerevisiae was analyzed at the molecular level through gene expression microarray analysis (Table S3). To accomplish this, the S. cerevisiae haploid laboratory strain BY4742 was treated with a sub-lethal concentration of 089 (0.2 mM), for 4 hours at 27 °C in shaking and compared the resulting transcriptional profile with the control transcriptional profile (cells treated with DMSO). Pathway signature analysis20 was carried out on the transcriptional profile induced by the treatment (Table S3). The results indicated impairment of the cell cycle, further supporting the targeting of Swe1p by 089 (Fig. 2b). Pathway analysis revealed that 089 allowed cells to proceed through the G1 and S phases and caused a cell arrest in the G2 phase (under-expression of genes related to the G1/S transition, to the E2F transcriptional targets at G1/S, and to the mitotic cell cycle pathways, Fig. 2b). In addition, a modification of cell morphology pathways was observable through pathway analysis, indicating a decrease in glycan structures (under-expression of their biosynthesis and over-expression of their degradation) and the inhibition of pseudo-hyphal filamentation or flocculation (genes controlled by Hms1p and Sfl1p). Furthermore, genes related to sphingolipid metabolism were also found over-expressed in response to the treatment with 089 (Table S3). The low number of gene sets differentially represented after 089 treatment and the fact that they are associated to only three main classes (cell cycle, morphology and lipid metabolism) is an indication of the molecule’s selectivity. To assess the novelty of the mechanism of action of the new compound 089, we compared the 089 HIPHOP profile with those of 3356 compounds published by Lee and coworkers16. The clustering of HIPHOP profiles and the following profiles grouping defined through the dynamic branch cutting method highlighted a 089 HIPHOP similarity to 27 HIPHOP profiles of the Lee database (Fig. S2). Embedded in the sub-cluster encompassing the 089 HIPHOP, there was a group of treatments identified to induce a modification of tryptophan biosynthesis and mitochondrial translation (Table S4)16. In addition, only two of the 089 co-clustering treatments have a known target (RER2 for both), coding a cis-prenyltransferase involved in dolichol synthesis and participating in endoplasmic reticulum protein sorting16.

### Validation and phenotypic effects of Swe1p targeting in S. cerevisiae by the 089 compound

HIP, HOP, and transcriptional analyses suggested that 089 impairs the S. cerevisiae cell cycle and arrests cells in the G2 phase. To validate this observation, we used flow-cytometry to quantify the DNA content of cells treated with 089 compared to the DNA content of control cells (treated with DMSO). To avoid the inclusion of budding cells in the analysis which would skew the quantification of single-cell DNA content, the DNA content was estimated only for cells showing forward and side scatter values similar to those of a culture of the BY4742 haploid strain. Cells of the haploid laboratory strain BY4742 were treated for 4 hours with a lethal concentration of 089 (0.3 mM) and their DNA content was determined by Propidium Iodide labeling in comparison to haploid BY4742 untreated cells and diploid cells obtained by crossing the BY4742 and W303 laboratory strains (Table 1). A significantly increased number of cells bearing a doubled content of DNA (characterizing the G2/M phase) was observed after treatment with 089 compared to DMSO (n = 3, 2-tailed t-test p < 0.01). Thus, flow-cytometry analysis confirmed that cells treated with the 089 molecule accumulated in the G2/M phase (Fig. S3a). The arrest of the cell cycle in the G2/M phase due to an altered Swe1p activity has previously been associated with reduced fidelity in bipolar budding23 and to an altered bud morphology24. In accordance with this, cells treated for 4 hours with 0.3 mM 089 showed an abnormal bud morphology: they elaborated multiple simultaneous budding events, indicating either that daughter cells do not separate after the budding or that multiple daughter cells emerge at the same time (Fig. S3b). A modification of cell morphology was also observed by means of pathway analysis on the transcriptional profiles induced by 089 treatment (Table S3), and in particular a decrease in glycan structures and the inhibition of pseudo-hyphal filamentation or flocculation were observed. To further support these observations, we evaluated the effects of combined treatments of S. cerevisiae cells with 089 and compounds known to modify cell wall composition or structure. We tested the combined effect of 089 with caspofungin (an echinocandin, inhibiting β-glucan biosynthesis), clotrimazole (an azole, inhibiting ergosterol biosynthesis), amphotericin B (forming pores on the cell membrane), and calcofluor white (binding chitin). BY4742 cells were treated for 24 hours at 28 °C with a lethal concentration of 089 (0.3 mM) and sub-lethal 089 concentrations (0.2 mM, 0.1 mM, and 0.05 mM) alone or combined with lethal or sub-lethal concentrations of the cell wall-affecting compounds (Fig. 3). Notably, the combination of the lowest tested 089 concentration (0.05 mM) and the lowest tested caspofungin concentration (0.0315 µg/ml) induced an effect statistically similar to the effect induced by the treatment with the lethal 089 concentration (0.3 mM; 2-tailed t-test, FDR > 0.05). A similar effect was observed in the 089-clotrimazole combined treatments. Nevertheless, the 089-clotrimazole combination was as lethal as 0.3 mM 089 only in the presence of 1.5 µg/ml clotrimazole (corresponding to the MIC). On the other hand, combined treatment with amphotericin B resulted in i) a reduction of the lethal effect of 0.3 mM 089, ii) a slight decrease of the cell growth in presence of 0.2 mM 089 or iii) no variations in the effects induced by lower 089 concentrations (Fig. 3). The combined treatment with calcofluor white had a similar effect, reducing the 0.3 mM 089 lethality and slightly increasing the effect of lower 089 concentrations. The changes in cell wall composition were also assessed by means of calcofluor white staining. BY4742 S. cerevisiae cells were inoculated in YPD supplemented with either 0.3 mM 089 or DMSO and treated for 4 hours at 28 °C with shaking. The cells treated with 089 showed a reduced labeling with calcofluor white compared to the control, especially when considering emerging new cells (Fig. S5).

Swe1p has also been recently shown to positively regulate sphingolipid biosynthesis by phosphorylating and inhibiting Orm proteins25. Also in this context, the targeting of SWE1 by 089 was confirmed by the observation that, after a 24 hours treatment with 0.3 mM 089, ceramides accumulated over free fatty acids, indicating an induction of de novo sphingolipid biosynthesis (Fig. S3c). We note that this effect was also observed at the pathway level through transcriptional analysis (Table S3).

### The 089 anti-fungal activity against pathogenic fungi

The increasing emergence of drug-resistant pathogenic fungal strains led us to consider the potential of 089 to inhibit the growth of clinically important pathogens. Hence, we assessed the effect of the treatment with 089 at various concentrations (0.3 mM, 0.2 mM, 0.1 mM) on the survival of Candida albicans and C. glabrata cells treated for 4 hours in YPD at 28 °C with shaking. After 4 hours treatment, we calculated the percentage of surviving cells as described in methods section. Following this assessment 100 live cells were plated onto YPD agar medium. After 4 days the CFU % (Colony Forming Units %) was calculated as the number of colonies formed by treated cells compared to the number of colonies formed by control cells. Each concentration of 089 induced a significant decrease in CFU in all the assayed yeast species (ANOVA test, Fisher post-hoc, p < 0.00001), indicating that 089 was effective also against pathogenic yeasts (Fig. 4a). The effects of 089 were also investigated using three different strains of Aspergillus fumigatus (Fig. S5a): a wild-type strain, A1160, and two azole-resistant strains, CYP51KO (deleted in the cyp51A gene and azole hyper-sensitive) and RFLS58 (an azole resistant environmental isolate). A. fumigatus conidia were inoculated at 2.5 × 105 spores/ml in MOPS-buffered RMPI 1640 medium supplemented with 2% glucose and several concentrations of 089 (serial dilutions from 1 mM to 0.025 mM) or DMSO as control. The treatment was carried out for 48 hours in static at 37 °C. At the end of the treatment, cultures were microscopically inspected to evaluate the cell survival and the cell morphology. The MIC (Minimum inhibitory concentration, the lowest concentration inducing fungal death) evaluated for azole-resistant strains CYP51ko was 1 mM, while for the A1160 reference strain was even higher (Fig. S5a). Nevertheless, a strong inhibition of the conidia germination induced by 089 was observable in all the tested strains (Fig. 4b). The MEC (Minimum Effective Concentration), considered as the minimal concentration inhibiting hyphae formation, differed among the tested A. fumigatus strains. The CYP51ko strain was the most sensitive (MEC = 0.3 mM) and the other azole-resistant strain (RFLS58) was the less sensitive to the treatment (MEC = 0.5 mM, Fig. S5a). To further characterize the effect of 089 on A. fumigatus, we first evaluated the internalization of the compound. We observed the localization of microscopic auto fluorescent drug particles before and after a PBS washing of treated cells (Fig. 4c). Before washing, drug granules were evident on the surface of conidia and germling cells excluding the view of cell contents, whereas after washing, the fluorescent compound was localised within the cell cytoplasm thus showing the ability of the compound to enter the cells (Fig. 4c). To further validate the inhibitory effect of 089 on A. fumigatus conidia germination, we measured swelling of A1160 A. fumigatus spores exposed to the compound (Fig. 4d). The area and volume of A1160 conidia treated with 0.4 mM 089 or with DMSO as control was measured in Sabouraud medium at 37 °C over a time course of 6 h. In the control treatment spores swelled evenly and continuously, but neither volume or area of conidia treated with 089 changed during the treatment (Fig. 4d). Treated spores did not germinate. (Fig. 4d). Since A. fumigatus often initiates infections in hyphal form, we also evaluated the effect of the compound on A. fumigatus hyphae (Fig. 4e). If the cell cycle inhibition induced by 089 observed in S. cerevisiae cells is conserved in A. fumigatus, fungal cells treated with the compound should not be able to grow and form multinucleate cells. Hence, we evaluated the number of nuclei in an A1160 strain expressing a GFP labelled Histone 1 protein (H1-sGFP). H1-sGFP treated with 089 compared to the control treatment (DMSO). Conidia were grown in Sabouraud media for 6 hours, allowing conidial germination. Afterwards, cells were treated with 0.4 mM 089 or with DMSO and images were acquired after 90 minutes every 10 minutes. The growth of hyphae treated with the 089 compound was clearly inhibited, as indicated by the fact that treated cells did not form elongated, polynucleated cells as in the control. Additionally, nuclei did not divide in cells treated with 089 (Fig. 4e and Supplementary Movie S1S3).

### The effects of 089 on Aspergillus fumigatus at the molecular level

The effects of 089 exposure on the A. fumigatus wild-type strain were investigated at the molecular level by means of RNA-sequencing analysis and compared to the transcriptional profile of a control culture (treated with DMSO). Conidia were inoculated at 2.5 × 105 conidia/ml in MOPS-buffered RPMI 1640 + 2% glucose supplemented with either 0.1 mM 089 or an equal volume of DMSO. After 4 hours of static growth at 37 °C, mycelium was frozen in liquid nitrogen, ground to a fine powder then RNA was extracted, and Illumina sequenced. Genes whose expression significantly changed between the treated and the control cultures (FDR < 0.05) were identified as DEGs (Differentially Expressed Genes). We found 436 DEGs compared to the control. Of these, 209 were under-expressed (their transcripts are more abundant in control samples than in treated samples, 166 with log2ratio < −2) and 227 were over-expressed (their transcripts are more abundant in the treated samples than in the control samples, 95 with log2ratio > 2) (Table S5). Considering the over-expressed genes, we found an enrichment in Gene Ontologies (GO) related to iron starvation response, response to drug, iron and phosphate transmembrane transport, and secondary metabolite biosynthesis (Table S6). These processes are known to be involved in a feedback loop regulation of the MAPK cell wall integrity pathway which is also involved in the regulation of phenotypes such as radial growth and conidiation26, thus possibly explaining the observed inhibition of A. fumigatus spore germination. By inspecting the phenotypic effects of the treatments on A. fumigatus cultures we observed an evident impairment of hyphae formation (Fig. 4c). Hence, we wondered whether this effect was also observable at the molecular level. To evaluate this, we compared the transcriptional profile induced by 089 with a set of transcriptional profiles obtained in A. fumigatus cells at different stages of the asexual cycle27, namely conidia (con), germinating conidia (GermCon) and hyphae (Hyph). To generate this dataset, Hagiwara and colleagues27 obtained DEGs by comparing the genes’ expression levels in: i) A. fumigatus conidia against hyphae (Con_vs_Hyp), ii) conidia against germinating conidia (Con_vs_GeC), or iii) germinating conidia against hyphae (GeC_vs_Hyp). The transcriptional profile of cells treated with the 089 compound clustered with the GeC_vs_Hyp profile, obtained by comparing germinating spores against hyphae (Fig. 5a). Hence, this similarity supported what observed at the phenotypic level (Fig. 4c). We went further and searched for groups of genes whose expression level was similar in the 089 treatment and in the GeC_vs_Hyp comparison but was the opposite in the Con_vs_GeC and Con_vs_Hyp profiles (Fig. 5a). We found two relevant sub-groups of genes: the first, indicated with “+” in Fig. 5a, was composed by genes over-expressed in the 089 treatment and in the GeC_vs_Hyp profiles and under-expressed in the Con_vs_Hyp and Con_vs_GeC profiles; the second, indicated with “−” in Fig. 5a, encompassed genes under-expressed in 089 and GeC_vs_Hyp profiles and over-expressed in Con_vs_Hyp and Con_vs_GeC profiles. Notably, the first set of genes (overexpressed in 089 and GeC_vs_Hyp and under-expressed in Con_vs_Hyp and Con_vs_GeC), was enriched in GOs related to ribosomes and to rRNA processing, synthesis and modification (Fig. S5b).

The effects observed at the molecular and phenotypic levels, both suggesting an impairment of asexual cell cycle progression in A. fumigatus and correspond with the impairment of cell cycle through Swe1p targeting observed in S. cerevisiae. To translate the 089 target identified in S. cerevisiae in opportunistic fungal infections we looked at the presence of SWE1 in common fungal pathogens. Both Candida glabrata and C. albicans bear orthologs of the candidate target SWE1 (CAGL0K00693g and C1_10010C_A, respectively, Fig. S6). Swe1p in C. albicans was shown to be required for full virulence, but not for filamentous growth. A. fumigatus contains an uncharacterized protein, Afu2g07690, with the highest sequence similarity to the S. cerevisiae Swe1p (the phylogenetic tree of the fungal orthologues is shown in Fig. S6). Despite SWE1 having two known homologs in humans (WEE1 and WEE2), 089 showed a moderate toxicity on mammalian cells, with none of the 089 tested concentrations significantly reducing cell survival (Fig. S7).

### Effects of 089 on fungal recognition by dendritic cells

Several pathogenic fungi (i.e. Candida spp.) switch their phenotype to invade the host tissue, evade the host immune response and shift it towards anti-inflammatory response28. Since 089 was shown to alter fungal ability to form hyphae which are more easily recognized by the host immune system, we investigated whether this effect could in turn modify the recognition of treated fungal cells by immune cells. We thus compared the in vitro ability of human monocyte-derived dendritic cells (DCs) to recognize and bind 089 treated S. cerevisiae, C. albicans and A. fumigatus cells. Aiming at observing potential improvements in the receptor recognition of viable yeast and fungal cells S. cerevisiae, C. albicans and A. fumigatus cells were treated with sub-lethal concentrations of the 089 compound (0.2 mM) for 4 hours. S. cerevisiae and C. albicans cells were treated in YPD at 28 °C with shaking, A. fumigatus cells were treated in MOPS-buffered RPMI medium at 37 °C in static. After the treatment, yeast and fungal cells were FITC-labeled and their binding (or internalization) by DC was measured through flow-cytometry (see materials and methods section for further details). DCs were able to bind or internalize a higher percentage of both C. albicans and A. fumigatus cells treated with 0.3 mM 089, compared to the same fungal cells exposed to DMSO only (Mann-Whitney p < 0.05, Fig. 5b).

## Discussion

The parallel utilization of several tools in the model yeast S. cerevisiae allowed the discovery of the mechanism of action of the new anti-fungal drug 089. We took advantage of the heterozygous barcoded deletion strain collection to identify drug targets and to observe affected and response pathways as well as using transcriptional profiling to uncover effects of the drug at the expression level in the entire cell. The combination of these techniques gives a complete picture of the effects induced by 089 treatment. The restricted number of potential targets identified by mean of HIP analysis may predict a high level of selectivity of the molecule. In confirmation the pathway level analysis only indicated effects directly associated to SWE1 targeting. The anti-fungal 089 acts on Swe1p, which controls cell cycle progression by delaying the G2/M transition through phosphorylation of Cdc28p. Both the phenotype and pathway analyses strongly support the Swe1p targeting by 089. While the deletion of the identified 089 target SWE1 induces an altered cell cycle kinetics with progression through the G2/M phase transition29, Swe1p over-expression induces cell arrest in G2/M (Fig. S3a)30. Hence, it could be hypothesized that 089 induces Swe1p activation. To note, the hypothesis that 089 activates Swe1p was further supported by the observation that the heterozygous HSL7 gene deletion strain showed a significantly positive FD after treatment with 089 (Fig. 1b). One of the functions of Hsl7p is to clear Swe1p from the cytosol. Thus, in the HSL7 heterozygous deletion strain, Swe1p accumulates in the cytosol, resulting in an effect similar to the one induced by 089. The arrest of the cell cycle in the G2/M phase caused by Swe1p over-expression has been associated to a reduced fidelity in bipolar budding23 and to an altered bud morphology24. The activation of Swe1p by 089 was further confirmed by the observation of the accumulation of ceramides over free fatty acids, indicating an induction of de novo sphingolipid biosynthesis (Fig. S3c). The potential counter-action of 089 and amphotericin B (especially at the 089 MIC, 0.3 mM) could be ascribed to the fact that amphotericin B acts by forming pores on the cell membrane and may be sensitive to the lipid/sphingolipid ratio. The observation that calcofluor white cell wall labeling of S. cerevisiae cells treated with 089 was reduced compared to the control treatment may suggest interplay between chitin synthesis and Swe1p, especially during early growth stages. Furthermore, the astonishingly high synergistic effect of 089 with caspofungin could be the result of a similar modification of the cell wall β-glucans content. Hence, the effect of 089 on Swe1p leads to a modification of cell morphology, observed both in S. cerevisiae and in A. fumigatus.

The HIPHOP profile induced by 089 treatment was similar to the HIPHOP profile induced by other chemicals16, but the mechanism of action of these compounds was unknown. In addition, the 089 HIPHOP profile clusters separately from the profiles of classical antifungals, confirming that this molecule acts through different mechanisms and does not trigger a response similar to the one induced by known antifungals in yeast cells. The 089 HIPHOP profile was similar to the HIPHOP profiles induced by two compounds (SGTC_1882 and SGTC_10) known to target the RER2 gene, involved in dolichol biosynthesis. Dolichol is one of the building blocks of membrane structure, hence, a defect in the synthesis of this acid, such as that induced either by the deletion of the RER2 gene31 or by its inhibition caused by treatments with SGTC_1882 and SGTC_1016, can trigger a downstream modification of cell morphology similar to that observed during treatment with 089. Concerning the other treatments clustering with 089, none of them was identified to have a specific target by Lee and colleagues16, probably because the Lee study was carried out on a smaller number of heterozygous deletion strains (only those deleted in essential genes) compared to the comprehensive pool used in the present work. It is thus possible that these compounds act on targets similar to that of 089, whose target, SWE1, was not included in Lee and co-workers’ heterozygous deletion collection. In general, 089 shows a HIPHOP profile different from common antfungals including several azoles, amphotericin and caspofungin. Changes in fungal cell morphology and hyphae formation that reveal fungal components to immune receptors are crucial for the ability of the host immune system to respond to the pathogen. Indeed, fungal cells treated with 089 appear to be recognized and bound by immune cells at higher frequency than untreated cells. The increased binding by dendritic cells could be the result of either the inability of treated Candida spp. and A. fumigatus cells to initiate hyphal growth or the cell wall re-arrangement caused by 089. However, we observed that the binding of dendritic cells to S. cerevisiae cells was not improved after the treatment with 089. The S. cerevisiae interaction with dendritic cells has been shown to be mediated by the exposure of specific cell wall components, rather than by the yeast morphology32. Hence, these results suggest that the inability to initiate hyphal growth is the main factor responsible for the increased recognition of Candida spp. and A. fumigatus cells. Several pathogenic fungi (i.e. Candida spp. and Aspergillus spp.) switch their phenotype to invade the host tissue, evade the host immune response and shift it towards anti-inflammatory response28, thus 089 could represent a promising compound to boost the immune response or synergistically act with the host immune response in eradicating fungal infection.

## Methods

### Strains used in this study

Yeast and fungal strains and the mammalian cell line used in this study are listed in Table 1. The Saccharomyces cerevisiae heterozygous and homozygous diploid barcoded deletion collections were generated in the BY4742 genetic background (Invitrogen). Transcriptional analyses on S. cerevisiae were carried out on the BY4742 laboratory strain. The validation of the 089 target was carried out on single strain cultures of the BY4741 strain deleted in either the HSL7, the SWE1 or the RNY1 genes, which were knocked out through replacement with the KANMX4 cassette conferring resistance to geneticin (Invitrogen). As reference for DNA content quantification through flow-cytometry, the haploid BY4742 and the diploid BY4742xW303 strains were used. The Candida albicans SC5314 (ATCC MYA-2876) reference strain, the C. glabrata YUC22 (a clinical isolate) were used to evaluate the 089 MIC in pathogenic yeasts (Table 1). Three strains of Aspergillus fumigatus from the Bowyer lab collection were used to evaluate the 089 effect on the pathogenic fungus (Table 1): A1160, a reference strain (akuB (KU80)-delta pyrG1 MAT1-1); CYP51, an azole-resistant strain derived from the reference A1160 strain by deleting the cyp51A gene ((cyp51A)-delta akuB (KU80)-delta pyrG1 MAT1-1); RFLS58, a clinical isolate resistant to azoles. To evaluate the 089 cytotoxicity on mammalian cells, the K562 (ATCC CCL-243) human cell line was used (Table 1).

### Growth media and conditions

The S. cerevisiae and Candida spp. strains were grown and treated at 27 °C with shaking in YP (1% w/v Yeast Extract, 2% w/v Peptone) supplemented with 2% w/v glucose. Before treatments, yeast cells were grown over night in the same medium and environmental conditions as the treatment experiment. Treatments with the compound (or with DMSO as control) were carried out on cells inoculated at 5 × 106 cells/ml concentration in YPD and treated in shaking at 27 °C.

Aspergillus fumigatus was grown on Sabouraud agar (1% w/v Peptone, 4% w/v glucose, 2% w/v agarose), at 37 °C. Conidia were collected from Sabouraud agar cultures using PBS + 0.1% Tween, avoiding collection of mycelial fragments and hyphae. The sample was filtered with a sterile filter with a pore diameter of 11 µm to remove hyphal fragments. Treatments with the compound were carried out in MOPS-buffered liquid RPMI 1640 medium (Euroclone) supplemented with 2% w/v glucose. The K562 cell line was grown in RPMI 1640 (Euroclone) supplemented with glutamine (Sigma Aldrich), penicillin and streptomycin (Sigma Aldrich), and 10% heat-inactivated fetal calf serum (Hyclone). The compound 089 ((7R)-3-benzhydryl-2-oxo-5-phenyl-6,8-dioxa-3-aza-bicycle[3.2.1]octane-7-carboxyl-ethylamide, MW = 442.51)15 was diluted in DMSO (DiMethyl SulfOxide) and added to the medium at the chosen concentration.

### Evaluation of the 089 effects on pathogenic yeasts and fungi

The Candida spp. strains were grown overnight in YPD medium and then inoculated in fresh medium at a final density of 5 × 106 cells/ml. The 089 compound was added to the medium at various concentrations (0.3 mM, 0.2 mM, 0.1 mM), DMSO was used as control. After 4 hours of treatment at 27 °C with shaking, the Candida spp. cells survival was evaluated with the Live/dead® Yeast Viability Kit (Life technologies), as indicated by the manufacturer. Candida spp. cells CFU% (Colony Forming Units percentage) was evaluated by plating in YPD agar 100 treated live yeast cells and counting colonies formed after at least 4 days. A. fumigatus treatments were performed following the EUCAST protocol33. A. fumigatus spores were collected from solid Sabouraud cultures using PBS + 0.1% Tween, avoiding mycelium fragments and hyphae collection. 2.5 × 105 spores/ml were inoculated in MOPS-buffered RPMI 1640 medium (Euroclone) supplemented with 2% w/v glucose. The effects of serial dilution of 089 ranging from 1 mM to 25 µM were assessed in 96-well plates using DMSO as control. Cultures were microscopically inspected after 48 hours of static growth at 37 °C. The treatment’s effects were read visually by recording the degree of growth for each well. The minimum effective concentration (MEC), defined as the lowest concentration of drug that results in macroscopic changes in filamentous growth to microcolonies or granular growth when compared with growth control wells, was evaluated for each A. fumigatus strain. For graphical reporting, the effect was scored as follows: 0 if all the cells were dead, 1 if no effects were observed compared to the control; between 0.25 and 0.75 for increasing hyphae formation inhibition.

### HIP HOP analyses

Both the homozygous and heterozygous barcoded-deletion pools (Table 1) were thawed and grown in YPD at 27 °C for 5 generations to allow cells to recover from freezing. Cells were then inoculated in 6 wells plates at 0.062 OD600 in YPD supplemented with 1% DMSO or 0.2 mM 089 (a sub-lethal compound concentration). Cells kept grown at 28 °C with shaking. Every five generations, 600 µl of the cultures were harvested and re-suspended with the same volume of YPD supplemented with the appropriate volume of DMSO or drug. After the 20th generation, cells were harvested, and genomic DNAs were extracted using QIAamp DNA Mini Kit (Qiagen) following manufacturer’s instructions. Three independent biological replicates were carried out for each treatment. Barcodes amplification was carried out as described in Smith et al.34 and detailed in Fig. S9. Three independent replicates were carried out for each treatment. Raw data were normalized and HIPHOP profiles were identified as previously described16. To quantify the sensitivity of the deletion strains to the compound, we calculated for every deletion strain a robust Z score (Fitness Defect score, FD), standardized to allow the comparison of different profiles16. Aiming at this, the log2ratio was calculated for each strain as in equation [1].

$$\mathrm{log}\,2{{\rm{ratio}}}_{i,j}=\frac{{{\rm{reads}}}_{i,ctrl}}{{{\rm{reads}}}_{i,j}}$$
(1)

where reads i,ctrl is the number of reads obtained for the ith deletion strain in the control (ctrl) treatment and reads i,j is the number of reads obtained for the ith deletion strain in the treatment j.

Then, the FDs were calculated as in equation [2].

$${{\rm{F}}{\rm{D}}}_{i,j}=media{n}_{R}[\frac{{{\rm{l}}{\rm{o}}{\rm{g}}2{\rm{r}}{\rm{a}}{\rm{t}}{\rm{i}}{\rm{o}}}_{i,j}-median({{\rm{l}}{\rm{o}}{\rm{g}}2{\rm{r}}{\rm{a}}{\rm{t}}{\rm{i}}{\rm{o}}}_{j})}{MAD({{\rm{l}}{\rm{o}}{\rm{g}}2{\rm{r}}{\rm{a}}{\rm{t}}{\rm{i}}{\rm{o}}}_{j})}]$$
(2)

where median R is the median among biological replicates and MAD is the Mean Absolute Deviation.

The concept of “clearance” was defined by Lee et al.16 and identifies hits that are substantially more significant than all other hits. After ordering the strains according to their FDs, the clearance is calculated as the difference of the FD of a given strain and of the closest strains. To identify strains significantly differing between the control and the treatment samples, we assumed that the FD scores followed a normal distribution in a screen and we calculated the probability that the given strain is an outlier in this distribution (one-sided p-value). Pathway analysis on HIP and HOP profiles was carried out by applying the Fisher’s exact test with EuGene analyzer on the list of significant strains20. Read counts of identified barcodes for each experiment were submitted to Array Express (E-SYBR-6) with the following sample names. 089_HIP: B722, B726, B730; DMSO_HIP: B721, B725, B729; 089_HOP: B695, B699, B703; DMSO_HIP: B692, B696, B700.

### HIP HOP meta-analysis

As an external dataset, the HIPHOP profiles produced by Lee and co-workers were downloaded from http://chemogenomics.pharmacy.ubc.ca/HIPHOP/16. The HIPHOP profiles were composed by strains deleted in essential genes in the heterozygous background and by strains deleted in non-essential genes in the homozygous background. Since our pools were composed by higher numbers of strains, we sub - divided them to make the profiles comparable. Then, the co-inhibition was calculated as described by Lee et al.16. The HIPHOP profiles are composed by significant FD scores (FD scores with p-values > 0.05 were replaced with 0), then the co-inhibition was calculated as the Pearson correlation between every couples of profiles. The significance of the correlation was estimated by using the Student’s t-distribution method. The clustering of profiles was then obtained by applying the Ward.D method of the hclust r function on the distances described as (1-coinhibition)35. Sub-clustering was identified in the obtained dendrogram using a dynamic branch cutting method by using the cutreeDynamic function of the dynamicTreeCut r package with the non-default parameter settings minimum cluster size = 3 and deepSplit = 436.

### Microarray transcriptional analysis

BY4742 S. cerevisiae cells were grown overnight in YPD medium. The day after, 1 × 109 cells were inoculated in 10 ml of fresh YPD supplemented with 0.2 mM 089 (sub-lethal concentration) or with DMSO. Cell cultures were incubated at 28 °C with shaking for 4 hours, then nitrogen frozen. RNA extraction was carried out as previously described15. Three independent biological replicates were carried out for each treatment. For hybridization onto Agilent 015072 Yeast Oligo Microarray 4 × 44 K 60mer oligonucleotide arrays (G2519F, Agilent), 300ng of total RNA were processed with the Agilent QuickAmp Labeling Kit, according to the manufacturer’s instructions. Fluorescent cDNA bound to the microarray was detected with a GenePix 4000B microarray scanner (Axon Instruments), using the GenePixPro6.1 software package to quantify microarray fluorescence. Data were normalized using the limma R package37 and DEGs (Differentially Expressed Genes) were identified with the RankProduct R package38. Raw and normalized data were submitted to GEO (GSE42418).

### Target validation – 089 effects on single cultures of S. cerevisiae deletion strains

Pure cultures of the heterozygous strains deleted in genes selected as potential 089 targets were grown in an overnight pre-culture in liquid YPD. Then, 105 cells/ml were inoculated in 96-well plates in fresh YPD supplemented with either various concentrations of 089 (0.1 mM, 0.2 mM, 0.3 mM, 0.4 mM, 0.5 mM) or a corresponding volume of DMSO. The Optical Density (OD) was then measured every two hours. The percentage of growth was calculated as the difference of the treated culture’s OD and the control culture’s OD at the stationary phase (24 hours after the inoculum) divided by the control culture’s OD. Mann-Whitney test was carried out searching for significant differences between controls and treatments.

### Target validation – quantification of DNA content in S. cerevisiae

The cell cycle of BY4742 cells treated for 4 hours with 0.3 mM 089 at 28 °C with shaking was assessed by DNA content determination using Propidium Iodide (PI) staining and flow cytometry as previously described39. Control cells were treated with equal volumes of DMSO. As reference, Nitrogen starved haploid BY4742 cells (1 N) or BY4742xW303 diploid cells (2 N) at the exponential growing phase were used40. Fixation and PI staining were carried out as previously described41. Events were sub-selected (gated) when showing similar forward scattering (proportional to the cell size) and side scattering (proportional to cell complexity) values similar to untreated reference yeast cultures. In addition, cells were further selected according to the distribution of events in the plot of pulse area versus pulse width, allowing the elimination of overlapping doublet events, as previously described42.

### Target validation – quantification of total cell lipid in S. cerevisiae

To quantify the total amounts of ceramides and fatty acids, cells treated for 24 h with 0.3 mM 089 or with DMSO as control were pelleted, washed with water, Nitrogen-frozen then dried. The quantification was carried out in three independent biological replicates. Cells were subjected to lipid and fatty acids extraction as previously described43. Briefly, 2 g harvested cells were mixed with 1 ml methanol. Cells were disrupted by adding 2 g of glass beads and vigorously shaking for 4 periods of 30 s with 30 s cooling in dry ice intervals. 2 ml chloroform were added to the supernatant and the suspension was stirred for 1 h at room temperature. The organic phase was then transferred in a new tube where 1 ml of 0.034% MgCl2 solution was added. The mix was stirred for 10 min, then the aqueous phase was removed, and the organic phase was washed with 1 ml of 2 N KCl/methanol (4:1. v/v). The mix was centrifuged, and the resulting organic phase was washed with a solution of chloroform/methanol/water (3:48:47; per volume). The mix was centrifuged, and the solvent of the organic phase was evaporated in a speed vacuum at 55 °C. The lipid film was finally dissolved in 0.5 ml chloroform/methanol (2:1, v/v), tightly sealed and stored at −20 °C. Extracted lipids and fatty acids were spotted on a silica TLC plate, which was developed as previously described44. Briefly, polar lipids were separated by developing the chromatogram in a saturated chamber in chloroform-methanol/water (65:30:5, v:v:v). The solvent front was allowed to migrate 4 cm from the lower edge of the plate. The solvent was evaporated, and the plate was further developed in n-hexane-diethyl ether-acetic acid (80:20:1.5, v:v:v) to separate neutral lipids. Lipids were visualized by spraying plates with 20% ethanolic phosphomolibdic acid and heating at 180 °C for 10 min. Hence, lipids were visualized as dark spots at different distances from the lower edge of the plate. Palmitic acid, stearic acid and non-hydroxy fatty acid ceramide standards were purchased by SIGMA and used as reference to identify the lipid classes present in the samples (by comparing the distance from the lower edge of the plate). Lipids were quantified by measuring the area of the corresponding spot.

### Target validation – effects of 089 on the S. cerevisiae cell wall organization

To further validate the effects of 089 on the S. cerevisiae cell wall composition, the chitin distribution in the cell wall was evaluated by means of staining with calcofluor white. BY4742 cells from an over-night culture were inoculated (5*106 cells/ml) in fresh YPD medium supplemented with 0.3 mM 089 (lethal concentration) or with DMSO (control). After four hours treatment, cells were washed with sterile water, the pellet was dissolved in 15 µl of sterile water and the cells were stained with calcofluor white (0.1 µg/ml). After one-minute incubation, cell membranes were visualized at a 100× magnification. Three independent biological replicates were carried out. The images of 10 randomly selected fields per replicate were captured.

### Assessment of the effects of anti-fungal combinations

To further explore the effect of the 089 compound, its effect on the survival of the laboratory S. cerevisiae strain BY4742 was evaluated in combination with antifungals modifying the yeast cell membrane. Aiming at this, the effects of all the combinations of four 089 concentrations (0.3 mM. 0.2 mM, 0.1 mM and 0.05 mM) and four concentrations of compounds impairing the cell membrane or wall composition were evaluated. The tested known compounds were: caspofungin (an echinocandin, inhibiting the β-glucan synthase), clotrimazole (an azole, inhibiting the biosynthesis of ergosterols), amphotericin B (acting by binding chitin and forming pores membrane on the cell membrane), and calcofluor white (binding the chitin). The tested concentrations included the MIC for S. cerevisiae and three lower concentrations. In particular, the tested concentrations were (for each compound, the highest one is the MIC): 0.252 µg/ml, 0.126 µg/ml, 0.063 µg/ml, and 0.0315 µg/ml for caspofungin; 3 µg/ml, 1.5 µg/ml, 0.75 µg/ml, and 0.375 µg/ml for clotrimazole; 1 µg/ml, 0.5 µg/ml, 0.25 µg/ml, and 0.125 µg/ml for amphotericin B; 25 µg/ml, 12.5 µg/ml, 6.25 µg/ml, and 3.125 µg/ml for calcofluor white. Cells from an over-night culture of the BY4742 strain were inoculated in fresh YPD medium supplemented with the compounds at various combinations or with DMSO as control. Each test was carried out in three independent biological replicates. After 24 hours treatment at 28 °C with shaking, the Optical Density of cultures was measured, and the survival percentage was calculated as in equation [3].

$${\rm{survival}}\, \% =\frac{{{\rm{OD}}}_{{\rm{t}}}\times 100}{{{\rm{OD}}}_{c}}$$
(3)

where ODt is the OD of the treated culture and ODc is the OD of the control culture. Significant differences were searched between the effect of each treatment and the effect of the lethal 089 concentration (0.3 mM) by mean of 2-tailed t-test. p-values were FDR corrected.

### Target validation – effects on Aspergillus fumigatus isotropic growth rate and nuclear division

The A1160 A. fumigatus strain was used to assess the effect of 089 on the fungal isotropic growth rate and nuclear division. The internalization of 089 drug granules within the fungal conidia/ germling was evaluated by observing microscopic auto fluorescent drug particles ~30 min post treatment. The localization of drug granules was assessed before and after washing twice the treated cells with PBS.

The volume and area of conidia treated with 0.4 mM 089 or with DMSO as control were measured using Imaris software (Bitplane, UK) of a confocal acquisition time lapse over 6 hours obtained using a Leica SP10 microscope.

To count the number of nuclei of germinated A. fumigatus conidia, an A1160 A. fumigatus strain expressing the labelled Histone 1 protein (H1-sGFP) was used. Conidia were grown in Sabouraud medium for 6 hours at 37 °C, then treated with 0.4 mM 089 or with DMSO as control. Images were captured every hour over a time course of 6 hours.

### Dendritic cells (DC) binding assay

The experimental plan was approved by the local Ethical Committee of the Careggi hospital (Florence, Italy, Ref. n. 87/10), and informed consent was obtained from all the healthy donors. All methods were performed in accordance with the relevant guidelines and regulations. Peripheral Blood Mononucleated Cells (PBMCs) were isolated from buffy coat blood samples from healthy volunteers by Ficoll-Hypaque density gradient centrifugation. Monocytes were isolated from low density PBMCs by magnetic enrichment with anti-CD14 beads (Miltenyi Biotec). After isolation, monocytes were cultured in RPMI 1640 supplemented with glutamine, penicillin and streptomycin, and 10% heat-inactivated fetal calf serum in the presence of GM-CSF (800 U/ml, Gentaur) and recombinant IL-4 (1000 U/ml, Gentaur) for 6 days to allow dendritic cells (DCs) differentiation48. S. cerevisiae, C. albicans and A. fumigatus cells were treated for 4 hours with sub-lethal concentrations of the 089 compound (0.2 mM). S. cerevisiae and C. albicans cells were treated in YPD at 28 °C with shaking, A. fumigatus cells were treated in MOPS-buffered RPMI medium at 37 °C in static. After the treatment, cells were washed with sterile water and the labelling of S. cerevisiae, C. albicans and A. fumigatus was performed before exposure to DCs as previously described49. FITC-labelled fungi were added in a fungal cell:DC ratio of 5:1. After 30 minutes of incubation at 37 °C, cell-fungi conjugates were analysed by flow cytometry. The binding of DCs to fungi was measured by flow cytometry using a FACS Calibur instrument (BD Biosciences). DCs were labelled with anti-CD11c-PE to discriminate cells binding FITC-labelled yeast/spores particles from yeast/spores aggregates. Mann-Whitney test was used to evaluate the statistical significance of the results by comparison between treated and untreated strains.

### Cytotoxicity on mammalian cells

K562 cells were grown in RPMI 1640 (Euroclone) supplemented with glutamine (Sigma), penicillin and streptomycin (SIGMA), and 10% heat-inactivated fetal calf serum (Hyclone). For toxicity assays, 3*105 cells/well were treated for 24 hours in 6-wells plates. Treatments were carried out with various concentrations of 089 (from 0.1 mM to 0.4 mM), ketoconazole (from 2.5 μM to 0.1 mM), or DMSO as control. Cell death induced by the treatments was assessed by the trypan blue exclusion technique. Survival percentage was evaluated as the number of live cells after the treatment with respect to the number of live cells after control treatment (cells grown without either the antifungals or DMSO). ANOVA statistics were used to evaluate differences among treatment effects.

### Comparison of SWE1 sequences in yeasts and fungi

To support the possibility that the same gene is targeted by 089 in different yeasts and fungi, we compared the S. cerevisiae Swe1p sequence with the available sequences of homologues in other yeasts and fungi. The S. cerevisiae Swe1p sequence was downloaded from the SGD website (date of access 26 August 2017)50. Ortholog sequences in fungi were retrieved from the OrthoDB database, using the S. cerevisiae Swe1p sequence as query51. The so-obtained sequences were then aligned with Muscle. The Neighbor-joining tree was inferred from distances calculated as the number of substitutions as a proportion of the length of the alignment (excluding gaps) with the Simple Phylogeny tool at EMBL-EBI52 and drawn with figtree (http://tree.bio.ed.ac.uk/).

## References

1. 1.

Perfect, J. R. The impact of the host on fungal infections. Am. J. Med. 125, S39–51 (2012).

2. 2.

Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med. 4, 165rv13 (2012).

3. 3.

Gallagher, J. Fungal infection “threat” to human health. BBC news, http://www.bbc.co.uk/news/health-3702215 (2016)

4. 4.

McNeil, M. M. et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33, 641–647 (2001).

5. 5.

Seabury, J. H. & Dascomb, H. E. Experience with amphotericin B for the treatment of systemic mycoses. AMA. Arch. Intern. Med. 102, 960–976 (1958).

6. 6.

Hamill, R. J. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 73, 919–934 (2013).

7. 7.

Nett, J. E. & Andes, D. R. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. Infect. Dis. Clin. North Am. 30, 51–83 (2016).

8. 8.

Mukherjee, P., & Wang, M. Antifungal Drug Resistance, in Antifungal Therapy (ed. Ghannoum, M.A. & Perfect, J.R.), 63–86. (CRC Press, 2009).

9. 9.

Anaissie, E. J. Immunomodulation for the treatment of invasive fungal infections. Clin. Infect. Dis. 26, 1264–1265 (1998).

10. 10.

Stevens, D. A. et al. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 38(Suppl 1), 305–315 (2000).

11. 11.

Clemons, K. V. & Stevens, D. A. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr. Opin. Infect. Dis. 19, 360–364 (2006).

12. 12.

Simitsopoulou, M. et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51, 1048–1054 (2007).

13. 13.

Pirofski, L. & Casadevall, A. The damage-response framework of microbial pathogenesis and infectious diseases. Adv. Exp. Med. Biol. 635, 135–146 (2008).

14. 14.

Chiller, T., Farrokhshad, K., Brummer, E. & Stevens, D. A. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 39, 99–103 (2001).

15. 15.

Stefanini, I., Trabocchi, A., Marchi, E., Guarna, A. & Cavalieri, D. A systems biology approach to dissection of the effects of small bicyclic peptidomimetics on a panel of saccharomyces cerevisiae mutants. J. Biol. Chem. 285, 23477–23485 (2010).

16. 16.

Lee, A. Y. et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 344, 208–211 (2014).

17. 17.

Giaever, G. & Nislow, C. The yeast deletion collection: A decade of functional genomics. Genetics 197, 451–465 (2014).

18. 18.

Harvey, S. L., Charlet, A., Haas, W., Gygi, S. P. & Kellogg, D. R. Cdk1-dependent regulation of the mitotic inhibitor Wee1. Cell 122, 407–420 (2005).

19. 19.

Cid, V. J., Shulewitz, M. J., McDonald, K. L. & Thorner, J. Dynamic localization of the Swe1 regulator Hsl7 during the Saccharomyces cerevisiae cell cycle. Mol. Biol. Cell 12, 1645–1669 (2001).

20. 20.

Beltrame, L. et al. Using pathway signatures as means of identifying similarities among microarray experiments. PLoS One 4, e4128 (2009).

21. 21.

Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).

22. 22.

Lee, T. I. et al. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298, 799–804 (2002).

23. 23.

Sheu, Y. J., Barral, Y. & Snyder, M. Polarized growth controls cell shape and bipolar bud site selection in Saccharomyces cerevisiae. Mol. Cell. Biol. 20, 5235–5247 (2000).

24. 24.

Enserink, J. M., Smolka, M. B., Zhou, H. & Kolodner, R. D. Checkpoint proteins control morphogenetic events during DNA replication stress in Saccharomyces cerevisiae. J. Cell Biol. 175, 729–741 (2006).

25. 25.

Chauhan, N. et al. Regulation of sphingolipid biosynthesis by the morphogenesis checkpoint kinase Swe1. J. Biol. Chem. 291, 2524–2534 (2016).

26. 26.

Valiante, V., Macheleidt, J., Föge, M. & Brakhage, A. A. The Aspergillus fumigatus cell wall integrity signaling pathway: drug target, compensatory pathways, and virulence. Front. Microbiol. 6, 325 (2015).

27. 27.

Hagiwara, D. et al. Comparative transcriptome analysis revealing dormant conidia and germination associated genes in Aspergillus species: an essential role for AtfA in conidial dormancy. BMC Genomics 17, 358 (2016).

28. 28.

Jacobsen, I. D. et al. Candida albicans dimorphism as a therapeutic target. Expert Rev. Anti. Infect. Ther. 10, 85–93 (2012).

29. 29.

Harvey, S. L. & Kellogg, D. R. Conservation of mechanisms controlling entry into mitosis: budding yeast wee1 delays entry into mitosis and is required for cell size control. Curr. Biol. 13, 264–275 (2003).

30. 30.

Booher, R. N., Deshaies, R. J. & Kirschner, M. W. Properties of Saccharomyces cerevisiae wee1 and its differential regulation of p34CDC28 in response to G1 and G2 cyclins. EMBO J. 12, 3417–3426 (1993).

31. 31.

Jin, R., Dobry, C. J., McCown, P. J. & Kumar, A. Large-scale analysis of yeast filamentous growth by systematic gene disruption and overexpression. Mol. Biol. Cell 19, 284–296 (2008).

32. 32.

Rizzetto, L. et al. Differential IL-17 production and mannan recognition contribute to fungal pathogenicity and commensalism. J. Immunol. 184, 4258–4268 (2010).

33. 33.

Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14, 982–984 (2008).

34. 34.

Smith, A. M. et al. Highly-multiplexed barcode sequencing: an efficient method for parallel analysis of pooled samples. Nucleic Acids Res. 38, e142 (2010).

35. 35.

R Core Team. (2012) R: a language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org/ (2014).

36. 36.

Langfelder, P., Zhang, B. & Horvath, S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics 24, 719–720 (2008).

37. 37.

Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).

38. 38.

Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).

39. 39.

Nickels, J. T. & Broach, J. R. A ceramide-activated protein phosphatase mediates ceramide-induced G1 arrest of Saccharomyces cerevisiae. Genes Dev. 10, 382–394 (1996).

40. 40.

Rivin, C. J. & Fangman, W. L. Cell cycle phase expansion in nitrogen-limited cultures of Saccharomyces cerevisiae. J. Cell Biol. 85, 96–107 (1980).

41. 41.

Paulovich, A. G. & Hartwell, L. H. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 82, 841–847 (1995).

42. 42.

Rosebrock, A. P. Analysis of the budding yeast cell cycle by flow cytometry. Cold Spring Harb. Protoc. 2017, 63–68 (2017).

43. 43.

Schneiter, R. & Daum, G. Extraction of yeast lipids. Methods Mol. Biol. 313, 41–45 (2006).

44. 44.

Kupke, I. R. & Zeugner, S. Quantitative high-performance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5-microliter samples to the silica-gel layer. J. Chromatogr. 146, 261–271 (1978).

45. 45.

Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 31, 46–53 (2013).

46. 46.

Maere, S., Heymans, K. & Kuiper, M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448–3449 (2005).

47. 47.

Lotia, S., Montojo, J., Dong, Y., Bader, G. D. & Pico, A. R. Cytoscape app store. Bioinformatics 29, 1350–1351 (2013).

48. 48.

Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 1109–1118 (1994).

49. 49.

Cambi, A. et al. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur. J. Immunol. 33, 532–538 (2003).

50. 50.

Cherry, J. M. et al. Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids Res. 40, D700–705 (2012).

51. 51.

Kriventseva, E. V. et al. OrthoDBv8: update of the hierarchical catalog of orthologs and the underlying free software. Nucleic Acids Res. 43, D250–256 (2015).

52. 52.

McWilliam, H. et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic Acids Res. 41, W597–W600 (2013).

## Acknowledgements

This project was supported by European Union’s Seventh Framework Programme [FP7/2007-2013] under grant agreement n° HEALTH-2010-242220 (“SYBARIS”) and by EU Framework Programme 7 Collaborative Project [242220]-JPI ENPADASI. I.S. was supported by the “Sybaris” project and by a fellowship from the Wellcome Warwick Quantitative Biomedicine Programme (Institutional Strategic Support Fund: 105627/Z/14/Z). The authors would like to thank Enrica Calura and Gavin Sherlock for support and critical comments on the analyses.

## Author information

Authors

### Contributions

D.C. and I.S. conceived the research, D.R., L.R., and I.S. carried out the BarSeq experiments, L.R. carried out immunology experiments, I.S. carried out the transcriptional analyses and the biological validation experiments, S.H. and I.S. carried out the bioinformatics analyses, S.C., I.G.G., M.G. and S.H. carried out the sequencing, N.B.G. and P.B. performed the validation experiments on Aspergillus fumigatus strains, I.S. wrote the paper, D.C. and M.K. supervised the project, A.G. and A.T. provided the 089 molecule and supervised the chemical analyses, P.B. provided the A. fumigatus strains. All the authors revised the manuscript.

### Corresponding authors

Correspondence to Irene Stefanini or Duccio Cavalieri.

## Ethics declarations

### Competing Interests

The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Stefanini, I., Rizzetto, L., Rivero, D. et al. Deciphering the mechanism of action of 089, a compound impairing the fungal cell cycle. Sci Rep 8, 5964 (2018). https://doi.org/10.1038/s41598-018-24341-y

• Accepted:

• Published:

• ### Bicyclic acetals: biological relevance, scaffold analysis, and applications in diversity-oriented synthesis

• Elena Lenci
• , Gloria Menchi
• , Fernanda I. Saldívar-Gonzalez
• , José L. Medina-Franco
•  & Andrea Trabocchi

Organic & Biomolecular Chemistry (2019)

• ### Vitamin B combination reduces fluconazole toxicity in Wistar rats

• Fahad A. Al-Abbasi
• , Saida Sadath
• , Gauhar Mushtaq
•  & Firoz Anwar

DARU Journal of Pharmaceutical Sciences (2019)